Topic: manufacturing expansion
Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.
Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.
WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.
Having only just completed an expansion in Illinois, PCI Pharma Services will now expand its solid dose facility in Wales in the U.K.
Thermo Fisher says it will put $24 million into its Scotland site on top of the $270 million it is investing in production at other sites this year.
Regeneron is humming along on the strength Eylea and Dupixent. Now, it’s expanding its production to keep up with that growth.
Nexus Pharmaceuticals has moved forward the first phase of a 10-year, $250 million project to build out its sterile drug production operations.
Catalent is buying a site in Italy from Bristol-Myers Squibb that handles biologics along with old-school solid-dose production.
Boehringer Ingelheim has invested €225 million on inhaler production with a new plant in Spain and expanded lines in Germany.
Aldevron unveiled plans to expand its North Dakota headquarters into a 14-acre campus.